Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Callies

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Experimental Child Psychology|November 26, 2008
Children's strategies in complex arithmeticPatrick Lemaire, Sophie Callies
Cancer Chemotherapy and Pharmacology|March 27, 2004
Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)Sophie Callies, Dinesh P de Alwis, Atul Mehta, et al.
British Journal of Clinical Pharmacology|February 3, 2011
Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotideSophie Callies, Valérie André, Bharvin Patel, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, James G Wright, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 14, 2006
Model-based drug development: the road to quantitative pharmacologyLiping Zhang, Vikram Sinha, S Thomas Forgue, et al.
Bioanalysis|February 17, 2018
Incorporating dried blood spot LC-MS/MS analysis for clinical development of a novel oncolytic agentEnaksha R Wickremsinhe, Sophie Callies, Chris A Schmalz, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2022
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationshipKazuhiko Nakagawa, Edward B Garon, Ling Gao, et al.
British Journal of Clinical Pharmacology|July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
Investigational New Drugs|February 3, 2015
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumorsJeffrey R Infante, Karim A Benhadji, Grace K Dy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 24, 2010
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanomaWilliam G Herrington, Denis C Talbot, Michael M Lahn, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Experimental Child Psychology|November 26, 2008
Children's strategies in complex arithmeticPatrick Lemaire, Sophie Callies
Cancer Chemotherapy and Pharmacology|March 27, 2004
Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979)Sophie Callies, Dinesh P de Alwis, Atul Mehta, et al.
British Journal of Clinical Pharmacology|February 3, 2011
Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotideSophie Callies, Valérie André, Bharvin Patel, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2003
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, James G Wright, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 14, 2006
Model-based drug development: the road to quantitative pharmacologyLiping Zhang, Vikram Sinha, S Thomas Forgue, et al.
Bioanalysis|February 17, 2018
Incorporating dried blood spot LC-MS/MS analysis for clinical development of a novel oncolytic agentEnaksha R Wickremsinhe, Sophie Callies, Chris A Schmalz, et al.
Cancer Chemotherapy and Pharmacology|July 16, 2022
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationshipKazuhiko Nakagawa, Edward B Garon, Ling Gao, et al.
British Journal of Clinical Pharmacology|July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
Investigational New Drugs|February 3, 2015
Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumorsJeffrey R Infante, Karim A Benhadji, Grace K Dy, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 24, 2010
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanomaWilliam G Herrington, Denis C Talbot, Michael M Lahn, et al.
Pageof 3